As of November 8, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of AEON Biopharma, Inc. The largest reported stake is Daewoong Co.,Ltd. ("DWC")'s, at 49.99%. 6 filings are on record since July 9, 2025 (Schedule 13D, January 29, 2026).
Sell to companies like AEON Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Timothy P. Lynch · Sole voting: 6,500,000 · Shared voting: 0 · Sole dispositive: 6,500,000 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-21
- · Reporting person: Stonepine Capital Management, LLC · Sole voting: 0 · Shared voting: 6,892,682 · Sole dispositive: 0 · Shared dispositive: 6,892,682 · SCHEDULE 13G, 2026-07-21
- · Holder: Daewoong Co.,Ltd. ("DWC") · Percent: 0.9% · SCHEDULE 13D/A
- · Holder: Daewoong Co.,Ltd. ("DWC") · Percent: 49.99% · SCHEDULE 13D
- · Holder: Alta Partners LLC · Percent: 2.1% · SCHEDULE 13G/A
AEON Biopharma, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-09. 3 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Daewoong Co.,Ltd. ("DWC") | 49.99% | 12,009,737 | SCHEDULE 13D, 2026-01-29 | 2026-01-21 |
| 13% | 6,500,000 | SCHEDULE 13G, 2026-08-21 | 2026-08-19 | |
| Stonepine Capital Management, LLC | 9.9% | 6,892,682 | SCHEDULE 13G, 2026-07-21 | 2026-07-15 |
| Alta Partners LLC | 2.1% | 249,870 | SCHEDULE 13G/A, 2025-10-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind AEON Biopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on AEON Biopharma, Inc. and the records around it.
AEON Biopharma, Inc. elsewhere on the record
Companies that share a holder
- Timothy P. Lynch also filed stake reports on 1 other company: Evolus, Inc. (Feb 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
Watch AEON Biopharma, Inc.
Get an email when AEON Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AEON Biopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on AEON Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AEON Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Timothy P. Lynch | 6,500,000 | 0 | 6,500,000 | 0 | SCHEDULE 13G, 2026-08-21 |
| Stonepine Capital Management, LLC | 0 | 6,892,682 | 0 | 6,892,682 | SCHEDULE 13G, 2026-07-21 |
| Stonepine Capital, L.P. | 0 | 6,892,682 | 0 | 6,892,682 | SCHEDULE 13G, 2026-07-21 |
| Stonepine GP, LLC | 0 | 6,892,682 | 0 | 6,892,682 | SCHEDULE 13G, 2026-07-21 |
| Jon M. Plexico | 0 | 6,892,682 | 0 | 6,892,682 | SCHEDULE 13G, 2026-07-21 |
The latest filing identifies AEON Biopharma, Inc. by CUSIP 00791X209 and gives its principal executive office as 130 VANTIS DRIVE, SUITE 170, ALISO VIEJO, CA 92656 (SCHEDULE 13G, 2026-08-21).
Purpose of Transaction (Item 4)
Daewoong Co.,Ltd. ("DWC")
The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. DWC is a shareholder of DWP with 52% of shares outstanding. DWP is the counterparty to the Issuer's license agreements for License & Supply Agreement, effective as of December 20, 2019, as amended, with DWP to provide the Issuer exclusive rights to commercialize and distribute ABP-450 in certain territories. Our future success currently depends entirely on the successful and timely regulatory approval and commercialization of the Issuer's only product candidate, ABP-450. The Issuer plans to develop ABP-450 to address the estimated $3.0 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by DWP, in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the FDA, Health Canada and EMA. The purpose of transaction is part of the Reporting Persons' efforts to strengthen the partnership with the Issuer, whose goal is to achieve development of ABP-450, for which the parties have previously worked together to gain certain approvals from the U.S. Food and Drug Administration (FDA). The Reporting Persons intend to review its investment in the Issuer on an ongoing basis, and currently have no intent to sell, transfer or otherwise …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-09 | Alta Partners LLC | 5.1% | SCHEDULE 13G/A |
| 2025-10-14 | Alta Partners LLC | 2.1% | SCHEDULE 13G/A |
| 2026-01-29 | Daewoong Co.,Ltd. ("DWC") | 0.9% | SCHEDULE 13D/A |
| 2026-01-29 | Daewoong Co.,Ltd. ("DWC") | 49.99% | SCHEDULE 13D |
| 2026-07-21 | Stonepine Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-08-21 | Timothy P. Lynch | 13% | SCHEDULE 13G |
Questions about who owns AEON Biopharma, Inc.
Who owns AEON Biopharma, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of AEON Biopharma, Inc.: Daewoong Co.,Ltd. ("DWC") (49.99%, Schedule 13D, filed 2026-01-29), Timothy P. Lynch (13%, Schedule 13G, filed 2026-08-21) and Stonepine Capital Management, LLC (9.9%, Schedule 13G, filed 2026-07-21).
Who are the largest shareholders of AEON Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of AEON Biopharma, Inc. on this page are Daewoong Co.,Ltd. ("DWC") (49.99%), Timothy P. Lynch (13%) and Stonepine Capital Management, LLC (9.9%).
When did Daewoong Co.,Ltd. ("DWC") buy into AEON Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Daewoong Co.,Ltd. ("DWC") on this page is the Schedule 13D/A, filed 2026-01-29, reporting 0.9%; its latest, Schedule 13D filed 2026-01-29, reports 49.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for AEON Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.